Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes
- 13 October 2025
- journal article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (1) , 104026
Abstract
No abstract availableKeywords
Funding Information
- China Pharmaceutical University
- Key Research and Development Projects of Shaanxi Province (2025GH-YBXM-069)
This publication has 53 references indexed in Scilit:
- A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital SettingPharmacoEconomics - Open, 2022
- Immune-related adverse events in various organs caused by immune checkpoint inhibitorsAllergology International, 2022
- Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vesselsClinical & Experimental Metastasis, 2021
- First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid TumorsThe Oncologist, 2021
- Lymphatic Distribution of Etanercept Following Intravenous and Subcutaneous Delivery to RatsPharmaceutical Research, 2020
- Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid TumorsJAMA Oncology, 2019
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functionsCancer Immunology, Immunotherapy, 2018
- Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in RatsPharmaceutical Research, 2011
- Demonstrating the Lymphatic System in Rats With MicroinjectionThe Anatomical Record, 2011
- Systemic Availability and Lymphatic Transport of Human Growth Hormone Administered by Subcutaneous InjectionJournal of Pharmaceutical Sciences, 2000